BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38205571)

  • 1. A Prospective Study of the Incidence of Chronic Xerostomia and the Quality of Life in Patients Undergoing Radiotherapy for Head and Neck Malignancies with IMRT or VMAT Techniques.
    Pathak NG; P M; Alok Y
    Gulf J Oncolog; 2024 Jan; 1(44):39-47. PubMed ID: 38205571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis.
    Ge X; Liao Z; Yuan J; Mao D; Li Y; Yu E; Wang X; Ding Z
    Support Care Cancer; 2020 Jun; 28(6):2701-2712. PubMed ID: 31673782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy.
    Lal P; Nautiyal V; Verma M; Yadav R; Maria Das KJ; Kumar S
    J Cancer Res Ther; 2018; 14(6):1196-1201. PubMed ID: 30488829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy.
    Baudelet M; Van den Steen L; Tomassen P; Bonte K; Deron P; Huvenne W; Rottey S; De Neve W; Sundahl N; Van Nuffelen G; Duprez F
    Head Neck; 2019 Oct; 41(10):3594-3603. PubMed ID: 31329343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Cohort Study Analyzing Radiation-Induced Xerostomia and Quality of Life of Head and Neck Cancer Patients Treated With Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy Techniques at a Tertiary Cancer Center in Eastern India.
    Sahoo B; Padhi S; Patra AC; Mahapatra BR; Mishra T; Mishra SR; Patro KC
    Cureus; 2023 Mar; 15(3):e36442. PubMed ID: 37090370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
    van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
    Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
    Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
    Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
    Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy.
    Pacholke HD; Amdur RJ; Morris CG; Li JG; Dempsey JF; Hinerman RW; Mendenhall WM
    Am J Clin Oncol; 2005 Aug; 28(4):351-8. PubMed ID: 16062076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.
    Daly ME; Lieskovsky Y; Pawlicki T; Yau J; Pinto H; Kaplan M; Fee WE; Koong A; Goffinet DR; Xing L; Le QT
    Head Neck; 2007 Mar; 29(3):211-20. PubMed ID: 17111429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy.
    Beetz I; Schilstra C; van Luijk P; Christianen ME; Doornaert P; Bijl HP; Chouvalova O; van den Heuvel ER; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):94-100. PubMed ID: 22169766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
    Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
    Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy: is xerostomia still prevalent?
    Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
    Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.